TSE:RVX Resverlogix (RVX) Stock Price, News & Analysis → Tech GIANT’s Plans to Revolutionize Crypto… (From Crypto 101 Media) (Ad) Free RVX Stock Alerts C$0.06 0.00 (0.00%) (As of 05/9/2024 ET) Add Compare Share Share Today's RangeC$0.06▼C$0.0650-Day RangeC$0.06▼C$0.0752-Week RangeC$0.05▼C$0.15Volume26,100 shsAverage Volume40,733 shsMarket CapitalizationC$16.33 millionP/E RatioN/ADividend Yield7.02%Price TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesStock AnalysisChartCompetitorsEarningsHeadlinesInsider Trades Get Resverlogix alerts: Email Address Ad Crypto 101 MediaElon Musk Secret Crypto Plot ExposedReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.Click here now to get your copy. About Resverlogix Stock (TSE:RVX)Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for disease states with high unmet medical needs. Its lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor that is in Phase III clinical trial for patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease, and neurodegenerative diseases. Resverlogix Corp. has a partnership with Eversana Life Science Services, LLC to support the pending launch of the commercialization of apabetalone for Covid-19 in the United States and Canada; and developing cardiovascular and pulmonary arterial hypertension indications. The company was founded in 2001 and is headquartered in Calgary, Canada.Read More RVX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RVX Stock News HeadlinesFebruary 21, 2024 | finance.yahoo.comResverlogix Announces Change to Its Board of DirectorsJanuary 11, 2024 | finance.yahoo.comResverlogix Announces Publication of its 40th Scientific Journal Article on Apabetalone's Potential Therapeutic BenefitsMay 11, 2024 | Paradigm Press (Ad)Dems have chosen Biden replacement?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in the 2024 presidential election.January 4, 2024 | theglobeandmail.comClosing Bell: Resverlogix Corp flat on Tuesday (RVX)December 19, 2023 | investing.comResverlogix Corp. (RVX) Earnings Dates & ReportsNovember 18, 2023 | morningstar.comResverlogix Corp RVXCFNovember 1, 2023 | morningstar.comResverlogix Corp RVXOctober 18, 2023 | theglobeandmail.comResverlogix: Top 10 Undervalued Healthcare Sector Stocks on TSX (RVX)May 11, 2024 | Crypto Swap Profits (Ad)Did You Get Your Free Bitcoin Yet?And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.October 4, 2023 | finanznachrichten.deResverlogix Corp.: Resverlogix Publishes on Apabetalone's Potential for the Treatment of FSHD, the Third Most Common Muscular DystrophyOctober 4, 2023 | finance.yahoo.comResverlogix Publishes on Apabetalone's Potential for the Treatment of FSHD, the Third Most Common Muscular DystrophySeptember 26, 2023 | finance.yahoo.comAtherosclerotic Cardiovascular Disease Market to Observe Impressive Growth at a CAGR of 2.2% by 2032, Predicts DelveInsightAugust 29, 2023 | finance.yahoo.comResverlogix Announces a Favorable Outlook Based on New Cardiovascular Disease Treatment Guidelines for Patients with Type 2 DiabetesAugust 24, 2023 | theglobeandmail.comClosing Bell: Resverlogix Corp up on Wednesday (RVX)August 14, 2023 | theglobeandmail.comClosing Bell: Resverlogix Corp flat on Monday (RVX)July 12, 2023 | theglobeandmail.comClosing Bell: Resverlogix Corp Warrants down on Wednesday (RVX-WT-A)June 29, 2023 | finance.yahoo.comResverlogix Announces Warrant Repricing and One-Year ExtensionJune 20, 2023 | finanznachrichten.deResverlogix Corp.: Resverlogix Announces Voting Results from the 2023 Meeting of ShareholdersJune 20, 2023 | finance.yahoo.comResverlogix Announces Voting Results from the 2023 Meeting of ShareholdersJune 12, 2023 | finance.yahoo.comResverlogix Announces New Insights into the Mechanism of Apabetalone's Cardioprotective Benefit in Chronic Kidney Disease PatientsJune 7, 2023 | finance.yahoo.comCanadian Investment Regulatory Organization Trading Halt - RVX.WT.AJune 6, 2023 | theglobeandmail.comClosing Bell: Resverlogix Corp Warrants down on Friday (RVX-WT-A)May 25, 2023 | theglobeandmail.comClosing Bell: Resverlogix Corp Warrants down on Tuesday (RVX-WT-A)May 18, 2023 | finance.yahoo.comCBOE RUSSELL 2000 VOLATILITY IN (^RVX)May 2, 2023 | theglobeandmail.comClosing Bell: Resverlogix Corp down on Monday (RVX)April 29, 2023 | theglobeandmail.comClosing Bell: Resverlogix Corp flat on Friday (RVX)April 28, 2023 | theglobeandmail.comClosing Bell: Resverlogix Corp Warrants flat on Thursday (RVX-WT-A)See More Headlines Receive RVX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Resverlogix and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/01/2024Today5/11/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeTSE SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolTSE:RVX CUSIPN/A CIKN/A Webwww.resverlogix.com Phone+1-403-2549252FaxN/AEmployees19Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)C($0.05) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeC$-12,820,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-37.10% Debt Debt-to-Equity RatioN/A Current Ratio0.11 Quick Ratio0.04 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowC$0.00 per share Price / Cash Flow132.50 Book ValueC($0.26) per share Price / Book-0.23Miscellaneous Outstanding Shares272,170,000Free FloatN/AMarket CapC$16.33 million OptionableNot Optionable Beta0.78 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesMr. Donald J. McCaffreyCo-Founder, Chairman, President, CEO & SecretaryMr. Aaron Bradley Cann C.A.CPA, CBV, Chief Financial OfficerDr. Ewelina Kulikowski Ph.D.Chief Scientific OfficerDr. Michael Sweeney M.D. (Age 63)Senior Vice President of Clinical Development Comp: $511.56kSarah ZapotichnyDirector of Investor Relations & Corporate CommunicationsKey CompetitorsReunion NeuroscienceTSE:REUNNeptune Wellness SolutionsTSE:NEPTAntibe TherapeuticsTSE:ATEKane BiotechCVE:KNESirona BiochemCVE:SBMView All Competitors RVX Stock Analysis - Frequently Asked Questions How have RVX shares performed in 2024? Resverlogix's stock was trading at C$0.07 on January 1st, 2024. Since then, RVX stock has decreased by 14.3% and is now trading at C$0.06. View the best growth stocks for 2024 here. How were Resverlogix's earnings last quarter? Resverlogix Corp. (TSE:RVX) announced its quarterly earnings results on Monday, April, 1st. The biotechnology company reported ($0.01) earnings per share for the quarter. What other stocks do shareholders of Resverlogix own? Based on aggregate information from My MarketBeat watchlists, some companies that other Resverlogix investors own include ProMetic Life Sciences (PLI), Aptose Biosciences (APTO), Oncolytics Biotech (ONC), Radient Technologies (RTI), VentriPoint Diagnostics (VPT), Endocyte (ECYT), Allena Pharmaceuticals (ALNA), Catalyst Pharmaceuticals (CPRX) and Royalty Pharma (RPRX). How do I buy shares of Resverlogix? Shares of RVX stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. This page (TSE:RVX) was last updated on 5/11/2024 by MarketBeat.com Staff From Our PartnersThe Crypto 9-5 Escape PlanCrypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchHow Biden has already won 2024Porter & CompanyRSVP: Charles Payne’s Cash Flow WorkshopUnstoppable ProsperityThe “Next Bitcoin”? 10 CENT Crypto Set to ExplodeTrue Market InsidersThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Resverlogix Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.